Research Site

Traverse City, Michigan 49686

1 studies enrolling now · 15 studies all time

What they study most

Acute Coronary Syndrome, Asthma, Breast Cancer, Carcinoma, Dyslipidemia, Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD), Hemophilia B, Hyperlipidemia, Metastases, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Neoplasm

Studies at this site

• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations — Recruiting now
• Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS — Recruiting now
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer — Running, not enrolling
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer — Running, not enrolling
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B — Completed
• Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia — Completed
• A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist — Completed
• Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 — Completed
• A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA — Completed
• Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). — Completed
• Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist — Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation — Completed
• Iressa Expanded Access Program (EAP) — Completed